Now showing items 1-1 of 1

    • A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. 

      Uronis, Hope E; Cushman, Stephanie M; Bendell, Johanna C; Blobe, Gerard C; Morse, Michael A; Nixon, Andrew B; Dellinger, Andrew; ... (13 authors) (Cancer Med, 2013-06)
      Targeting multiple regulators of tumor angiogenesis have the potential to improve treatment efficacy. Bevacizumab is a monoclonal antibody directed against vascular endothelial growth factor and ABT-510 is a synthetic analog ...